KALA BIO INC (KALA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.51-9.57%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KALA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||
| Revenues | — | — | — | 0.0 | 3.9 | 11.2 | 6.4 | 6.1 | — | 0.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 0.0 |
| Operating Expenses & Income | ||||||||||
| Selling, General & Admin | — | — | — | 20.6 | 65.0 | 105.1 | 81.1 | 65.0 | 35.4 | — |
| R&D Expenses | — | — | — | — | — | — | 18.4 | 27.3 | 29.3 | 29.0 |
| Other Operating Expenses, Total | — | — | — | — | — | (12.4) | (8.1) | (6.1) | (2.0) | (2.3) |
| Operating Income | (21.0) | (39.2) | (41.0) | (39.7) | (81.7) | (130.2) | (96.2) | (88.2) | (64.7) | (39.9) |
| Earnings from Continuing Operations | ||||||||||
| Interest Expense | — | 3.3 | 5.8 | 5.8 | 7.3 | 8.4 | 8.6 | 8.5 | 3.3 | 1.0 |
| Interest & Investment Income | 0.5 | 1.1 | 2.1 | 2.7 | 0.7 | 0.1 | 0.5 | 2.4 | 1.7 | 0.5 |
| Net Interest Expenses | — | — | — | 3.1 | 6.6 | 8.3 | 8.1 | 6.1 | 1.6 | 0.5 |
| Other Non-Operating Income / Expenses | 10.9 | 12.2 | 2.5 | (2.5) | 36.9 | (12.4) | — | — | — | — |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | ||||||||||
| Net Income | (10.1) | (27.0) | (38.5) | (42.2) | (44.8) | (142.6) | (104.3) | (94.3) | (66.7) | (42.2) |
| Per Share | ||||||||||
| Basic EPS | (135.92) | (3.31) | (10.15) | (17.35) | (29.48) | (108.32) | (1.99) | — | — | — |
| Diluted EPS | (135.92) | (3.31) | (10.15) | (17.35) | (29.48) | (108.32) | (1.99) | — | — | — |
| Basic Weighted Avg Shares | 0.1 | 8.1 | 3.8 | 2.4 | 1.5 | 1.3 | 52.4 | — | — | — |
| Diluted Weighted Avg Shares | 0.1 | 8.1 | 3.8 | 2.4 | 1.5 | 1.3 | 52.4 | — | — | — |
| Supplemental | ||||||||||
| EBITDA | — | (38.8) | (40.7) | (39.4) | (81.2) | (129.3) | (95.3) | — | — | — |
| EBIT | (21.0) | (39.2) | (41.0) | (39.7) | (81.7) | (130.2) | (96.2) | (88.2) | (64.7) | (39.9) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.